Publications in collaboration with researchers from Hospital del Mar (28)

2025

  1. Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer

    Molecular Medicine, Vol. 31, Núm. 1

2024

  1. Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines

    International Journal of Molecular Sciences, Vol. 25, Núm. 1

2023

  1. miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer

    Cancers, Vol. 15, Núm. 7

2022

  1. CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer

    Journal of Clinical Medicine, Vol. 11, Núm. 6

  2. Role of SALL4 in HER2+ Breast Cancer Progression: Regulating PI3K/AKT Pathway

    International Journal of Molecular Sciences, Vol. 23, Núm. 21

  3. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

    Science Advances, Vol. 8, Núm. 20

  4. mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer

    Molecular Cancer Research, Vol. 20, Núm. 7, pp. 1108-1121

2021

  1. Expression of phosphorylated brd4 is markedly associated with the activation status of the pp2a pathway and shows astrong prognostic value in triple negative breast cancer patients

    Cancers, Vol. 13, Núm. 6, pp. 1-11

  2. Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer

    Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5096-5108

  3. Targeted therapy modulates the secretome of cancer-associated fibroblasts to induce resistance in her2-positive breast cancer

    International Journal of Molecular Sciences, Vol. 22, Núm. 24

  4. The novel oral mtorc1/2 inhibitor tak-228 reverses trastuzumab resistance in her2-positive breast cancer models

    Cancers, Vol. 13, Núm. 11

2020

  1. Autocrine CCL5 effect mediates trastuzumab resistance by ERK pathway activation in HER2-positive breast cancer

    Molecular Cancer Therapeutics, Vol. 19, Núm. 8, pp. 1696-1707

  2. MicroRNA-33b Suppresses Epithelial–Mesenchymal Transition Repressing the MYC–EZH2 Pathway in HER2+ Breast Carcinoma

    Frontiers in Oncology, Vol. 10

  3. The hippo pathway transducers yap1/tead induce acquired resistance to trastuzumab in her2-positive breast cancer

    Cancers, Vol. 12, Núm. 5

2019

  1. High numbers of circulating CD57+ NK cells associate with resistance to her2-specific therapeutic antibodies in HER2+ primary breast cancer

    Cancer Immunology Research, Vol. 7, Núm. 8, pp. 1280-1292

  2. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Recent insights into the development of preclinical trastuzumab-resistant HER2+ breast cancer models

    Current Medicinal Chemistry, Vol. 25, Núm. 17, pp. 1976-1998

2017

  1. CIP2A confirms its prognostic value in triple-negative breast cancer

    Oncogene

  2. Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer

    Clinical Cancer Research, Vol. 23, Núm. 22, pp. 7006-7019

  3. The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene

    Scientific Reports, Vol. 7